Plasminogen activator inhibitor-1 polymorphism is associated with progressive renal dysfunction after acute rejection in renal transplant recipients

Transplantation

Volumn 74, Issue 12, 2002, Pages 1791-1794

  Chow, Kai Ming ^a   Szeto, Cheuk Chun ^a   Szeto, Carol Yi Ki ^a   Poon, Peter ^a   Lai, Fernand Mac Moune ^a   Li, Philip Kam Tao ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ALLELE; ARTICLE; BLOOD LEVEL; CREATININE BLOOD LEVEL; FEMALE; FIBRINOLYSIS; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION;

EID: 0037184798     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200212270-00026     Document Type: Article

References (15)

1. Sankaran D, Asderakis A, Ashraf S, et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 1999;56:281-288.
2. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002;283:F209-220.
3. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-1801.
4. Wang Y, Pratt JR, Tam FW, et al. Up-regulation of type 1 plasminogen activator inhibitor messenger RNA with thrombotic changes in renal grafts. Transplantation 1996;61:684-689.
5. Wang Y, Pratt JR, Hartley B, et al. Expression of tissue type plasminogen activator and type I plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure. Kidney Int 1997;52:371-377.
6. Delarue F, Hertig A, Alberti C, et al. Prognostic value of plasminogen activator inhibitor type 1 mRNA in microdissected glomeruli from transplanted kidneys. Transplantation 2001;72:1256-1261.
7. Verpooten GA, Cools FJ, Van der Planken MG, et al. Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. Nephrol Dial Transplant 1996;11:347-351.
8. Duymelinck C, Dauwe SE, Nouwen EJ, et al. Cholesterol feeding accentuates the cyclosporine-induced elevation of renal plasminogen activator inhibitor type 1. Kidney Int 1997;51:1818-1830.
9. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;15:10739-10745.
10. Wong TY, Poon P, Szeto CC, et al. Association of plasminogen activator inhibitor-1, 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int 2000;57:632-638.
11. Matsubara Y, Murata M, Isshiki I, et al. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels. Int J Hematol 1999;69:43-47.
12. Ishikawa A, Flechner SM, Goldfarb DA, et al. Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome. Transplantation 1999;68:1318-1324.
13. Boekholdt SM, Bijsterveld NR, Moons AH, et al. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: A systematic review. Circulation 2001;104:3063-3068.
14. Menges T, Hermans PW, Little SG, et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001;357:1096-1097.
15. Sarnak MJ, Levey AS. Progression of renal insufficiency: Methods of assessment. In: Massry SG, Glassock RJ, eds. Massry & Glassock's Textbook of Nephrology [Ed. 4]. Philadelphia, Lippincott Williams & Wilkins 2001, pp 1207-1210.